154 related articles for article (PubMed ID: 37748107)
21. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma.
Norasetthada L; Tantiworawit A; Rattanathammethee T; Chai-Adisaksopha C; Chaipoh T; Rattarittamrong E
J Hematol; 2018 Dec; 7(4):131-139. PubMed ID: 32300428
[TBL] [Abstract][Full Text] [Related]
23. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
[TBL] [Abstract][Full Text] [Related]
24. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
[TBL] [Abstract][Full Text] [Related]
25. Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.
Tanaka N; Imai Y; Yoshinaga K; Shiseki M; Tanaka J
Ann Hematol; 2020 Nov; 99(11):2577-2586. PubMed ID: 32945942
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Torka P; Groman A; Wong J; Nichols J; Kader A; Mavis C; Anampa-Guzmán A; Sait SJ; Block A; Przespolewski E; Mohr A; Lund I; McWhite K; Kostrewa J; DeMarco J; Johnson M; Darrall A; Thomas R; Sundaram S; Ghione P; Hutson A; Hernandez-Ilizaliturri FJ
Blood Adv; 2023 Apr; 7(7):1146-1155. PubMed ID: 36375132
[TBL] [Abstract][Full Text] [Related]
27. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
28. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
Witzens-Harig M; Memmer ML; Dreyling M; Hess G
BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
[TBL] [Abstract][Full Text] [Related]
30. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
32. R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.
Montoro J; Andreola G; Gardellini A; Babic A; Negri M; Frungillo N; Martinelli G; Laszlo D
Transfus Apher Sci; 2014 Jun; 50(3):411-4. PubMed ID: 24751603
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
34. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Cuccuini W; Briere J; Mounier N; Voelker HU; Rosenwald A; Sundstrom C; Cogliatti S; Hirchaud E; Ysebaert L; Bron D; Soulier J; Gaulard P; Houlgatte R; Gisselbrecht C; Thieblemont C
Blood; 2012 May; 119(20):4619-24. PubMed ID: 22408263
[TBL] [Abstract][Full Text] [Related]
35. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
Kambhampati S; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
[TBL] [Abstract][Full Text] [Related]
36. Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis.
Li T; Yu J; Hou M; Zha S; Cheng Q; Zheng Q; Li L
Pharmacol Res; 2023 Jan; 187():106592. PubMed ID: 36470547
[TBL] [Abstract][Full Text] [Related]
37. Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or ref7ractory ALK+ anaplastic large cell lymphoma.
Ding Y; Lu H; Dong Y; Xiu B; Liang A; Zhang W
Oncol Lett; 2023 Jun; 25(6):268. PubMed ID: 37216160
[TBL] [Abstract][Full Text] [Related]
38. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
Imataki O; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1629-32. PubMed ID: 17940378
[TBL] [Abstract][Full Text] [Related]
40. [Clinical Efficacy Comparison of Different Second Line Salvage Chemotherapy Regimens for the Treatment of Elderly Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma].
Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):448-51. PubMed ID: 27151008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
